Valneva’s Chikungunya Vaccine Candidate Awarded EMA Prime Designation
Valneva today announced that the European Medicines Agency (EMA) has granted PRIority MEdicines (PRIME) designation for its single-shot Phase 3 chikungunya vaccine candidate VLA1553.